Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
Cabaletta Bio (NASDAQ: CABA) announced upcoming presentations featuring updated clinical data on resecabtagene autoleucel (rese-cel) at two scientific meetings in February 2025. The presentations will cover safety, translational data, and clinical outcomes from the first 10 patients dosed with rese-cel across multiple ongoing RESET™ clinical trials.
The data will be presented at the 2025 American Association for the Advancement of Science Annual Meeting in Boston (February 13-15) and the 5th International Conference on Lymphocyte Engineering in Munich (February 20-22). The presentations will focus on rese-cel's application in treating autoimmune diseases, including Myositis, SLE, and Systemic Sclerosis.
Cabaletta Bio (NASDAQ: CABA) ha annunciato prossime presentazioni con dati clinici aggiornati su resecabtagene autoleucel (rese-cel) in due incontri scientifici a febbraio 2025. Le presentazioni riguarderanno la sicurezza, i dati traslazionali e i risultati clinici dei primi 10 pazienti trattati con rese-cel nell'ambito di diversi trial clinici RESET™ in corso.
I dati saranno presentati al 2025 American Association for the Advancement of Science Annual Meeting a Boston (dal 13 al 15 febbraio) e al 5th International Conference on Lymphocyte Engineering a Monaco (dal 20 al 22 febbraio). Le presentazioni si concentreranno sull'applicazione di rese-cel nel trattamento delle malattie autoimmuni, inclusi la Miocite, il LES e la Sclerosi Sistemica.
Cabaletta Bio (NASDAQ: CABA) anunció presentaciones próximas con datos clínicos actualizados sobre resecabtagene autoleucel (rese-cel) en dos reuniones científicas en febrero de 2025. Las presentaciones cubrirán la seguridad, los datos traslacionales y los resultados clínicos de los primeros 10 pacientes tratados con rese-cel en múltiples ensayos clínicos RESET™ en curso.
Los datos se presentarán en la Reunión Anual de la Asociación Americana para el Avance de la Ciencia 2025 en Boston (del 13 al 15 de febrero) y en la 5ª Conferencia Internacional sobre Ingeniería de Linfocitos en Múnich (del 20 al 22 de febrero). Las presentaciones se centrarán en la aplicación de rese-cel en el tratamiento de enfermedades autoinmunitarias, incluyendo Miopatía, LES y Esclerosis Sistémica.
Cabaletta Bio (NASDAQ: CABA)는 2025년 2월 두 개의 과학 회의에서 resecabtagene autoleucel (rese-cel)에 대한 업데이트된 임상 데이터를 다룰 예정이라고 발표했습니다. 이 발표에서는 RESET™ 임상 시험에 참여한 첫 10명의 환자에게 투여된 rese-cel의 안전성, 번역 데이터 및 임상 결과를 다룰 것입니다.
이 데이터는 보스턴에서 개최되는 2025 미국과학진흥협회 연례 회의(2월 13-15일)와 뮌헨에서 열리는 제5회 국제 림프구 공학 회의(2월 20-22일)에서 발표됩니다. 발표는 미오시스, 전신홍반루푸스(SLE), 전신경화증을 포함한 자가면역 질환 치료에 대한 rese-cel의 적용에 초점을 맞출 것입니다.
Cabaletta Bio (NASDAQ: CABA) a annoncé des présentations à venir présentant des données cliniques mises à jour sur resecabtagene autoleucel (rese-cel) lors de deux réunions scientifiques en février 2025. Les présentations couvriront la sécurité, les données translationnelles et les résultats cliniques des 10 premiers patients traités avec rese-cel dans le cadre de plusieurs essais cliniques RESET™ en cours.
Les données seront présentées lors de la Réunion Annuelle de l'Association Américaine pour l'Avancement de la Science 2025 à Boston (du 13 au 15 février) et à la 5ème Conférence Internationale sur l'Ingénierie des Lymphocytes à Munich (du 20 au 22 février). Les présentations se concentreront sur l'application de rese-cel dans le traitement des maladies auto-immunes, y compris la myosite, le lupus érythémateux systémique (LES) et la sclérose systémique.
Cabaletta Bio (NASDAQ: CABA) kündigte bevorstehende Präsentationen mit aktualisierten klinischen Daten zu resecabtagene autoleucel (rese-cel) auf zwei wissenschaftlichen Tagungen im Februar 2025 an. Die Präsentationen werden die Sicherheit, translationale Daten und klinische Ergebnisse der ersten 10 Patienten, die mit rese-cel behandelt wurden, aus mehreren laufenden RESET™ klinischen Studien abdecken.
Die Daten werden auf dem 2025 American Association for the Advancement of Science Annual Meeting in Boston (13.-15. Februar) und auf der 5th International Conference on Lymphocyte Engineering in München (20.-22. Februar) präsentiert. Die Präsentationen konzentrieren sich auf die Anwendung von rese-cel zur Behandlung von Autoimmunerkrankungen, darunter Myositis, systemischer Lupus erythematodes (SLE) und systemische Sklerose.
- None.
- None.
PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that updated clinical data on resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) will be featured in presentations at the 2025 American Association for the Advancement of Science Annual Meeting, which is being held at the Hynes Convention Center in Boston, MA from February 13-15, 2025, and the 5th International Conference on Lymphocyte Engineering, which is being held at the Holiday Inn Munich – City Center in Munich, Germany from February 20-22, 2025. The presentations will include safety, translational data and clinical outcomes from the first 10 patients dosed with rese-cel across multiple ongoing clinical trials in the RESET™ clinical development program.
Details of the presentations are as follows:
2025 American Association for the Advancement of Science Annual Meeting
Session: Science Breakthroughs
Title: Unleashing Immune Cells on Autoimmune Disease
Date and Time: Saturday, February 15, 2025, 10:00 a.m. – 11:00 a.m. ET
Presenter: Aimee Payne, M.D., Ph.D., Irving Professor and Chair of Dermatology at Columbia University, Co-founder of and Scientific Advisory Board Co-chair at Cabaletta Bio
5th International Conference on Lymphocyte Engineering
Session: Session 9: Targeting Non-malignant Diseases
Title: Clinical and Translational Studies of Rese-cel (an anti-CD19 CAR T Therapy) in Myositis, SLE, and Systemic Sclerosis: RESET Phase I/II Trials
Date and Time: Saturday, February 22, 2025, 10:15 a.m. – 10:30 a.m. CET
Presenter: Samik Basu, M.D., Chief Scientific Officer at Cabaletta Bio
Additional information can be accessed on the website of each scientific meeting. Presentation materials will be made available on the Posters & Publications section of the Company’s website following each event.
About rese-cel (formerly referred to as CABA-201)
Rese-cel is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy for patients with autoimmune diseases where B cells contribute to the initiation and/or maintenance of disease. Following a one-time infusion of a weight-based dose, rese-cel is designed to transiently and completely deplete all CD19-positive cells. This approach has the potential to reset the immune system and result in compelling clinical responses without chronic therapy requirements in patients. Cabaletta is currently evaluating rese-cel in the RESET™ (REstoring SElf-Tolerance) clinical development program which includes multiple disease-specific, company-sponsored clinical trials across growing portfolios of autoimmune diseases in a broad range of therapeutic areas, including rheumatology, neurology and dermatology.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
FAQ
What clinical data will be presented for CABA's rese-cel in February 2025?
Which autoimmune conditions is CABA's rese-cel being tested for in the RESET trials?
Where will CABA present its rese-cel clinical data in February 2025?
How many patients' data will be included in CABA's February 2025 rese-cel presentations?
